Literature DB >> 11673087

HPRT mutations in humans: biomarkers for mechanistic studies.

R J Albertini1.   

Abstract

The X-chromosomal gene for hypoxanthine-guanine phosphoribosyltransferase (HPRT), first recognized through its human germinal mutations, quickly became a useful target for studies of somatic mutations in vitro and in vivo in humans and animals. In this role, HPRT serves as a simple reporter gene. The in vivo mutational studies have concentrated on peripheral blood lymphocytes, for obvious reasons. In vivo mutations in T cells are now used to monitor humans exposed to environmental mutagens with analyses of molecular mutational spectra serving as adjuncts for determining causation. Studies of the distributions of HPRT mutants among T cell receptor (TCR) gene-defined T cell clones in vivo have revealed an unexpected clonality, suggesting that HPRT mutations may be probes for fundamental cellular and biological processes. Use of HPRT in this way has allowed the analyses of V(D)J recombinase mediated mutations as markers of a mutational process with carcinogenic potential, the use of somatic mutations as surrogate markers for the in vivo T cell proliferation that underlies immunological processes, and the discovery and study of mutator phenotypes in non-malignant T cells. In this last application, the role of HPRT is related to its function, as well as to its utility as a reporter of mutation. Most recently, HPRT is finding use in studies of in vivo selection for in vivo mutations arising in either somatic or germinal cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11673087     DOI: 10.1016/s1383-5742(01)00064-3

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  28 in total

1.  In vivo 6-thioguanine-resistant T cells from melanoma patients have public TCR and share TCR beta amino acid sequences with melanoma-reactive T cells.

Authors:  Cindy L Zuleger; Michael D Macklin; Bret L Bostwick; Qinglin Pei; Michael A Newton; Mark R Albertini
Journal:  J Immunol Methods       Date:  2010-12-21       Impact factor: 2.303

2.  Biological monitoring and surveillance results of Gulf War I veterans exposed to depleted uranium.

Authors:  Melissa A McDiarmid; Susan M Engelhardt; Marc Oliver; Patricia Gucer; P David Wilson; Robert Kane; Michael Kabat; Bruce Kaup; Larry Anderson; Dennis Hoover; Lawrence Brown; Richard J Albertini; Rama Gudi; David Jacobson-Kram; Craig D Thorne; Katherine S Squibb
Journal:  Int Arch Occup Environ Health       Date:  2005-08-02       Impact factor: 3.015

3.  Depleted uranium exposure and health effects in Gulf War veterans.

Authors:  Katherine S Squibb; Melissa A McDiarmid
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-04-29       Impact factor: 6.237

Review 4.  Direct mutation analysis by high-throughput sequencing: from germline to low-abundant, somatic variants.

Authors:  Michael Gundry; Jan Vijg
Journal:  Mutat Res       Date:  2011-10-12       Impact factor: 2.433

5.  High rate of mutation reporter gene inactivation during human T cell proliferation.

Authors:  Aida Gabdoulkhakova; Gunnel Henriksson; Nadezhda Avkhacheva; Alexander Sofin; Anders Bredberg
Journal:  Immunogenetics       Date:  2006-12-19       Impact factor: 2.846

Review 6.  Applications of the human p53 knock-in (Hupki) mouse model for human carcinogen testing.

Authors:  Ahmad Besaratinia; Gerd P Pfeifer
Journal:  FASEB J       Date:  2010-04-06       Impact factor: 5.191

7.  A conditional predictive p-value to compare a multinomial with an overdispersed multinomial in the analysis of T-cell populations.

Authors:  Qinglin Pei; Cindy L Zuleger; Michael D Macklin; Mark R Albertini; Michael A Newton
Journal:  Biostatistics       Date:  2013-10-04       Impact factor: 5.899

8.  Evidence of genetic instability in tumors and normal nearby tissues.

Authors:  Giuseppe Geraci; Ida D'Elia; Rosanna del Gaudio; Rossella Di Giaimo
Journal:  PLoS One       Date:  2010-02-23       Impact factor: 3.240

9.  Epigallocatechin-3-gallate decreases UVA-induced HPRT mutations in human skin fibroblasts accompanied by increased rates of senescence and apoptosis.

Authors:  Yang Xu; Jie Zhu; Bingrong Zhou; Dan Luo
Journal:  Exp Ther Med       Date:  2012-01-31       Impact factor: 2.447

10.  Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease.

Authors:  Truc Nguyen; Pamela M Vacek; Patrick O'Neill; Richard B Colletti; Barry A Finette
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.